Azora Therapeutics (AZR) vs Boundless Bio (BOLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Azora Therapeutics is the larger company by market cap ($55.0 million vs $54.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AZR | BOLD |
|---|---|---|
| Share price | $3.85 | $2.32 |
| Market cap | $55.00M | $54.78M |
| 1-day change | -0.52% | -2.52% |
| YTD return | — | +93.33% |
| 1-year return | — | +105.31% |
| EPS (TTM) | $-18.09 | $-2.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.98M | $-58.20M |
| 52-week high | $8.25 | $3.16 |
| 52-week low | $1.31 | $0.961 |
| Distance from 52-week high | -53.33% | -26.68% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +72.41% |
| Average volume | 50.12K | 131.34K |
| Shares outstanding | 14.29M | 23.61M |
| Employees | — | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
AZR vs BOLD FAQ
Which is bigger, Azora Therapeutics or Boundless Bio?
Azora Therapeutics (AZR) is larger, with a market capitalization of $55.00M compared with $54.78M for Boundless Bio (BOLD).
Are Azora Therapeutics and Boundless Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.